[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2002022080A8 - Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications - Google Patents

Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications

Info

Publication number
WO2002022080A8
WO2002022080A8 PCT/US2001/028861 US0128861W WO0222080A8 WO 2002022080 A8 WO2002022080 A8 WO 2002022080A8 US 0128861 W US0128861 W US 0128861W WO 0222080 A8 WO0222080 A8 WO 0222080A8
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
nef
pol
gag
vaccines
Prior art date
Application number
PCT/US2001/028861
Other languages
French (fr)
Other versions
WO2002022080A3 (en
WO2002022080A9 (en
WO2002022080A2 (en
Inventor
Emilio A Emini
Rima Youil
Andrew J Bett
Ling Chen
David C Kaslow
John W Shiver
Timothy J Toner
Daniel R Casimiro
Original Assignee
Merck & Co Inc
Emilio A Emini
Rima Youil
Andrew J Bett
Ling Chen
David C Kaslow
John W Shiver
Timothy J Toner
Daniel R Casimiro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2002526335A priority Critical patent/JP2004508064A/en
Priority to AU2001294562A priority patent/AU2001294562B2/en
Priority to AU9456201A priority patent/AU9456201A/en
Priority to EP01975214A priority patent/EP1320621A4/en
Priority to US10/380,641 priority patent/US20040101957A1/en
Priority to CA002422882A priority patent/CA2422882A1/en
Application filed by Merck & Co Inc, Emilio A Emini, Rima Youil, Andrew J Bett, Ling Chen, David C Kaslow, John W Shiver, Timothy J Toner, Daniel R Casimiro filed Critical Merck & Co Inc
Publication of WO2002022080A2 publication Critical patent/WO2002022080A2/en
Publication of WO2002022080A3 publication Critical patent/WO2002022080A3/en
Publication of WO2002022080A8 publication Critical patent/WO2002022080A8/en
Publication of WO2002022080A9 publication Critical patent/WO2002022080A9/en
Priority to US11/599,584 priority patent/US20070054395A1/en
Priority to US11/604,553 priority patent/US20070077257A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

First generation adenoviral vectors and associated recombinant adenovirus-based HIV vaccines which show enhanced stability and growth properties and greater cellular-mediated immunity are described within this specification. These adenoviral vectors are utilized to generate and produce through cell culture various adenoviral-based HIV-1 vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof. These adenovirus vaccines, when directly introduced into living vertebrate tissue, preferably a mammalian host such as a human or a non-human mammal of commercial or domestic veterinary importance, express the HIV1- Gag, Pol and/or Nef protein or biologically modification thereof, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, encoding codon optimized HIV-1 Pol, derivatives of optimized HIV-1 Pol (including constructs wherein protease, reverse transcriptase, RNAse H and integrase activity of HIV-1 Pol is inactivated), HIV-1 Nef and derivatives of optimized HIV-1 Nef, including nef mutants which effect wild type characteristics of Nef, such as myristylation and down regulation of host CD4. The adenoviral vaccines of the present invention, when administered alone or in a combined modality regime, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.
PCT/US2001/028861 2000-09-15 2001-09-14 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications WO2002022080A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AU2001294562A AU2001294562B2 (en) 2000-09-15 2001-09-14 Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications
AU9456201A AU9456201A (en) 2000-09-15 2001-09-14 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
EP01975214A EP1320621A4 (en) 2000-09-15 2001-09-14 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
US10/380,641 US20040101957A1 (en) 2001-09-14 2001-09-14 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications
CA002422882A CA2422882A1 (en) 2000-09-15 2001-09-14 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
JP2002526335A JP2004508064A (en) 2000-09-15 2001-09-14 Enhanced first generation adenovirus vaccine expressing codon-optimized HIV1-GAG, POL, NEF and modifications
US11/599,584 US20070054395A1 (en) 2000-09-15 2006-11-13 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications
US11/604,553 US20070077257A1 (en) 2001-09-14 2006-11-27 Enhanced first generation adenovirus vaccines expressing condon optimized HIV1-Gag, Pol, Nef and modifications

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23318000P 2000-09-15 2000-09-15
US60/233,180 2000-09-15

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/599,584 Continuation US20070054395A1 (en) 2000-09-15 2006-11-13 Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-Gag, Pol, Nef and modifications

Publications (4)

Publication Number Publication Date
WO2002022080A2 WO2002022080A2 (en) 2002-03-21
WO2002022080A3 WO2002022080A3 (en) 2002-05-02
WO2002022080A8 true WO2002022080A8 (en) 2003-01-16
WO2002022080A9 WO2002022080A9 (en) 2003-03-06

Family

ID=22876220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/028861 WO2002022080A2 (en) 2000-09-15 2001-09-14 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications

Country Status (5)

Country Link
EP (1) EP1320621A4 (en)
JP (1) JP2004508064A (en)
AU (2) AU2001294562B2 (en)
CA (1) CA2422882A1 (en)
WO (1) WO2002022080A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001043693A2 (en) * 1999-12-17 2001-06-21 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
DK1436397T3 (en) 2001-10-11 2010-08-09 Merck Sharp & Dohme Hepatitis C virus vaccine
US7479547B2 (en) 2001-10-31 2009-01-20 The South African Medical Research Council HIV-1 subtype isolate regulatory/accessory genes, and modifications and derivatives thereof
AU2003220237A1 (en) * 2002-03-13 2003-09-29 Merck & Co., Inc. Method of inducing an enhanced immune response against hiv
JP4413012B2 (en) 2002-03-29 2010-02-10 メルク エンド カムパニー インコーポレーテッド Virus production method
ATE494362T1 (en) 2002-05-14 2011-01-15 Merck Sharp & Dohme METHOD FOR PURIFYING ADENOVIRUS
CN1490056A (en) * 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� Immune method and composition for HIV-1
WO2004037294A2 (en) 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
CA2507915C (en) 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
CA2512365A1 (en) 2003-01-03 2004-07-22 Gennaro Ciliberto Rhesus her2/neu, nucleotides encoding same, and uses thereof
CN101173282B (en) 2003-07-21 2011-04-06 P.安杰莱蒂分子生物学研究所 Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
GB2406336A (en) * 2003-09-24 2005-03-30 Oxxon Pharmaccines Ltd HIV Pharmaccines
EP1716173B8 (en) 2004-02-11 2012-06-27 Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. Carcinoembryonic antigen fusion protein and uses thereof
CA2555412C (en) 2004-02-23 2013-06-25 Crucell Holland B.V. Virus purification methods
EP2567967A3 (en) * 2004-04-12 2013-08-21 GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of using adenoviral vectors to induce an immune response
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
AP2351A (en) 2004-10-13 2012-01-25 Crucell Holland Bv Improved adenoviral vectors and uses thereof.
US8574595B2 (en) 2005-04-11 2013-11-05 Crucell Holland B.V. Virus purification using ultrafiltration
AU2012201827B2 (en) * 2005-05-12 2014-09-04 Glaxo Group Limited Vaccine composition
PE20061372A1 (en) * 2005-05-12 2007-01-16 Glaxo Group Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ADENOVIRUS VECTOR
JP5361386B2 (en) 2005-10-07 2013-12-04 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ Matrix metalloproteinase 11 vaccine
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
CL2008000611A1 (en) * 2007-03-02 2008-09-05 Glaxosmithkline Biolog Sa PROCEDURE TO PROMOTE IMMUNE RESPONSE AGAINST A PATHOGEN UNDERSTANDING I) ONE OR MORE IMMUNOGENIC POLYPEPTIDES DERIVED FROM THE PATHOGEN, II) ONE OR MORE ADENOVIRICAL VECTORS UNDERSTANDING ONE OR MORE POLINUCLEODICS
MX342449B (en) 2007-08-03 2016-09-29 Pasteur Institut Lentiviral gene transfer vectors and their medicinal applications.
EP2047861B1 (en) * 2007-10-12 2019-07-31 Institut Pasteur Lentiviral gene transfer vectors suitable for iterative administration and their medicinal applications
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
SI2358757T1 (en) * 2008-11-18 2018-12-31 Beth Israel Deaconess Medical Center Antiviral vaccines with improved cellular immunogenicity
EP3173096A1 (en) 2011-04-06 2017-05-31 Biovaxim Limited Pharmaceutical compositions for preventing and/or treating an hiv disease in humans
SG11201405228VA (en) 2012-03-12 2014-11-27 Crucell Holland Bv Batches of recombinant adenovirus with altered terminal ends
US8932607B2 (en) 2012-03-12 2015-01-13 Crucell Holland B.V. Batches of recombinant adenovirus with altered terminal ends
SG11201503864TA (en) 2012-11-16 2015-06-29 Beth Israel Hospital Recombinant adenoviruses and use thereof
US20180052173A1 (en) 2015-03-18 2018-02-22 Janssen Vaccines & Prevention B.V. Assays for recombinant expression systems
PL3283634T3 (en) 2015-04-14 2019-10-31 Janssen Vaccines & Prevention Bv Recombinant adenovirus expressing two transgenes with a bidirectional promoter
EP3472327B1 (en) 2016-06-20 2020-08-19 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
EP3704138A1 (en) 2017-10-31 2020-09-09 Janssen Vaccines & Prevention B.V. Adenovirus and uses thereof
EA202091104A1 (en) 2017-10-31 2020-08-12 Янссен Вэксинс Энд Превеншн Б.В. ADENOVIRUS AND WAYS OF ITS APPLICATION
MX2020004490A (en) 2017-10-31 2020-08-13 Janssen Vaccines & Prevention Bv Adenovirus vectors and uses thereof.
EA202091074A1 (en) 2017-10-31 2020-07-22 Янссен Вэксинс Энд Превеншн Б.В. ADENOVIRUS AND ITS APPLICATIONS
WO2019118480A1 (en) 2017-12-11 2019-06-20 Beth Israel Deaconess Medical Center, Inc. Recombinant adenoviruses and uses thereof
CN111057716B (en) * 2019-07-27 2022-04-15 中国人民解放军军事科学院军事医学研究院 Single plasmid vector system for packaging recombinant human adenovirus type 4 and application thereof
KR20220076497A (en) 2019-10-03 2022-06-08 얀센 백신스 앤드 프리벤션 비.브이. Adenoviral vectors and uses thereof
CN112522276B (en) * 2020-12-15 2022-07-15 武汉纽福斯生物科技有限公司 EMC1 nucleotide sequence and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643579A (en) * 1984-11-01 1997-07-01 American Home Products Corporation Oral vaccines
FR2705686B1 (en) * 1993-05-28 1995-08-18 Transgene Sa New defective adenoviruses and corresponding complementation lines.
WO1996009399A2 (en) * 1994-09-23 1996-03-28 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US5872005A (en) * 1994-11-03 1999-02-16 Cell Genesys Inc. Packaging cell lines for adeno-associated viral vectors
WO1996039178A1 (en) * 1995-06-05 1996-12-12 The Wistar Institute Of Anatomy And Biology A replication-defective adenovirus human type 5 recombinant as a vaccine carrier
US6019978A (en) * 1995-06-05 2000-02-01 The Wistar Institute Of Anatomy And Biology Replication-defective adenovirus human type 5 recombinant as a vaccine carrier
WO1999002647A2 (en) * 1997-07-10 1999-01-21 Hepavec Ag Für Gentherapie Cloning vectors for producing adenoviral minimal viruses
GB9803351D0 (en) * 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6670188B1 (en) * 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
AU6139699A (en) * 1998-09-11 2000-04-03 Children's Medical Center Corporation Packaging cell lines for hiv-derived retroviral vector particles
WO2000039302A2 (en) * 1998-12-31 2000-07-06 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
GB9906177D0 (en) * 1999-03-17 1999-05-12 Oxford Biomedica Ltd Anti-viral vectors
GB9912965D0 (en) * 1999-06-03 1999-08-04 Oxford Biomedica Ltd In vivo selection method
WO2001045748A1 (en) * 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
DE60026199T2 (en) * 2000-05-18 2006-11-23 Geneart Ag Synthetic genes for gagpol and their uses
EP2302059A1 (en) * 2000-08-14 2011-03-30 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Modifications of hiv Env, Gag, and Pol enhance immunogenicity for genetic immunization

Also Published As

Publication number Publication date
AU2001294562B8 (en) 2002-03-26
WO2002022080A3 (en) 2002-05-02
EP1320621A2 (en) 2003-06-25
JP2004508064A (en) 2004-03-18
WO2002022080A9 (en) 2003-03-06
CA2422882A1 (en) 2002-03-21
AU2001294562B2 (en) 2007-05-24
AU9456201A (en) 2002-03-26
WO2002022080A2 (en) 2002-03-21
EP1320621A4 (en) 2005-11-23

Similar Documents

Publication Publication Date Title
WO2002022080A8 (en) Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
JP6368416B2 (en) Antiviral vaccine with improved cellular immunogenicity
Gao et al. Recent progress in vaccine development against chikungunya virus
WO2003038057A3 (en) Genetic vaccine against human immunodeficiency virus
Rosario et al. Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques
WO2021000968A3 (en) Adenovirus carrier vaccine used for preventing sars-cov-2 infection
Bailey An assessment of the role of chimpanzees in AIDS vaccine research
EA002020B1 (en) Method in generating an antiviral immune response in a human or an animal
ATE354370T1 (en) INACTIVATED IMMUNOGENIC BACTERIAL WHOLE CELL COMPOSITIONS
Puls et al. Therapeutic vaccination against HIV: current progress and future possibilities
Gudmundsdotter et al. Therapeutic immunization for HIV
Li et al. Efficient augmentation of a long-lasting immune responses in HIV-1 gag DNA vaccination by IL-15 plasmid boosting
WO2003077859A3 (en) Method of inducing an enhanced immune response against hiv
Vanniasinkam et al. Adenoviral gene delivery for HIV-1 vaccination
Du et al. Improvement in efficacy of DNA vaccine encoding HIV-1 Vif by LIGHT gene adjuvant
WO2003076598A3 (en) Method of inducing an enhanced immune response against hiv
Mooij et al. Synthetic long peptide booster immunization in rhesus macaques primed with replication-competent NYVAC-C-KC induces a balanced CD4/CD8 T-cell and antibody response against the conserved regions of HIV-1
Blancou et al. Simian immunodeficiency virus promoter exchange results in a highly attenuated strain that protects against uncloned challenge virus
DE60330795D1 (en) VACCINE AGAINST WEST NILE VIRUS
Boberg et al. Vaccination against drug resistance in HIV infection
Douglass et al. Modifications to the HIV-1 SAAVI MVA-C vaccine improve in vitro expression and in vivo immunogenicity
Williamson The Development of HIV‐1 Subtype C Vaccines for Southern Africa
Fiorentini et al. HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens
Bourinbaiar et al. Clinical experience with therapeutic AIDS vaccines
Devadas et al. Selective side-chain modification of cysteine and arginine residues blocks pathogenic activity of HIV-1-Tat functional peptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 56/144-134/144, DRAWINGS, REPLACED BY NEW PAGES 56/144-134/144; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

121 Ep: the epo has been informed by wipo that ep was designated in this application
WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGES 56/144-134/144, DRAWINGS, REPLACED BY CORRECT PAGES 56/144-134/144

WWE Wipo information: entry into national phase

Ref document number: 2001975214

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2001294562

Country of ref document: AU

Ref document number: 10380641

Country of ref document: US

Ref document number: 2002526335

Country of ref document: JP

Ref document number: 2422882

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2001975214

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001294562

Country of ref document: AU